Wednesday, February 26, 2014 8:59:59 AM
If you haven’t heard of the company so far, it’s important to mention Nuvilex, Inc. deals with biotechnology. Specifically, they are aiming to make cancer treatments available on a massive scale. Diabetes is also a priority for them and research conducted for cancer treatments will also focus on diabetes. Their business advantage lies in the newly patented encapsulated cells platform. Nuvilex, Inc. has a great deal of experience in cancer biology and clinical oncology. By combining that experience with their new research efforts, they are trying to explore various application of medical marijuana.
Research
The entire medical marijuana movement wouldn’t even exist were it not for extensive research of the subject matter. Before this legalization wave, research was scarce. Only a handful of studies were done and they didn’t say much we didn’t already know. However, as the green revolution picked up, countries all over the world became inspired to do some actual scientific research on the advantages and disadvantages of medical marijuana. In example, we have already written about Tikun Olam, an Israeli company that produces medical marijuana with 0% THC and 15% CBD, which is astonishing. We hoped more companies would follow suit. And some of them did. Now, Nuvilex is looking to dive into the medical marijuana research territory, an effort that just might make their stock jump up from excitement.
New BioTechnology
Just recently, Nuvilex has acquired the rights to a form of encapsulation technology that is based on cellulose live-cells. If you don’t speak science, the entire thing is called Cell-in-a-BoxTM. This will serve as the basis for cancer treatment, as well as diabetes. In example, the treatment Nuvilex proposes to patients suffering from pancreatic cancer should be done through administration ifosfamide, a well-known anticancer drug. What some of you may not know is that Nuvilex has a subsidiary under the name Medical Marijuana Sciences, Inc.
That particular information is of outmost interest to us, medical marijuana enthusiasts. The subsidiary is focused on developing different ways of treating cancer with the main research compound being marijuana. Currently, they are trying to figure out how to implement the above mentioned Cell-in-a-BoxTM into their medical marijuana research. The sudden boost is thought to stem from the recent support of medical marijuana by President Obama. If he and his administration stand behind their statements, we might see some serious funding for medical marijuana research.
Stocks & Markets
Supposedly, companies that deal with anti-cancer stocks have seen an increase in the last couple of months, which means investors are looking to invest into biotech. Considering the fact marijuana is on everyone’s mind these days, Nuvilex might see a similar increase in the near future. We will keep you updated on further developments regarding Nuvilex, Inc. Who knows, we just might have another Tikun Olam on our hands.
http://www.medicalmarijuanablog.com/benefits/nuvilex-thriving-in-the-field-0f-medical-marijuana.html?utm_source=rss&utm_medium=rss&utm_campaign=rss
Recent PMCB News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/13/2024 04:19:35 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/13/2024 08:37:40 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM